Royal United Hospital

Running trials

• Not yet recruiting

  Diagnosis of Women With ANOCA

  NCT07802457· NHS Greater Glasgow and Clyde· Source

• Not yet recruiting

  Exercise Therapy for Women With ANOCA

  NCT07733986· NHS Greater Glasgow and Clyde· Source

• Recruiting

  Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer

  NCT07831902· Phase 3· University College, London· Source

• Recruiting

  A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

  NCT07230691· Janssen Research & Development, LLC· Source

• Recruiting

  Optimising the Delivery of Diabetes Distress Informed Care for Its Prevention, Detection, and Management in Adults With Type 1 Diabetes: a Feasibility Study (D-stress Study)

  NCT07193446· Guy's and St Thomas' NHS Foundation Trust· Source

• Recruiting

  A Trial of "APL-9796'' in Adults With Pulmonary Hypertension

  NCT06846554· Phase 2· Apollo Therapeutics Ltd· Source

• Active, not recruiting

  A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis

  NCT06718101· Phase 2· AbbVie· Source

• Active, not recruiting

  Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib

  NCT06531109· Pfizer· Source

• Active, not recruiting

  A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

  NCT06544616· Phase 2· Janssen Pharmaceutica N.V., Belgium· Source

• Recruiting

  A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  NCT06161025· Phase 2/3· Daiichi Sankyo· Source

• Active, not recruiting

  CGM Use in Adults With Type 2 Diabetes on Basal Insulin

  NCT05944432· Abbott Diabetes Care· Source

• Recruiting

  GEKO Venous Thromboembolism Prevention Study

  NCT05476913· Firstkind Ltd· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

  NCT05501886· Phase 3· Celcuity Inc· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

  NCT05508789· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

  NCT05296798· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Hemithyroidectomy or Total-Thyroidectomy in 'Low-risk' Thyroid Cancers

  NCT05604963· University College, London· Source

• Active, not recruiting

  Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

  NCT04136353· Phase 3· University of Sydney· Source

• Active, not recruiting

  ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss

  NCT04065269· Phase 2· Institute of Cancer Research, United Kingdom· Source

• Recruiting

  MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

  NCT04116502· Phase 3· University of Birmingham· Source

• Active, not recruiting

  A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

  NCT03345823· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

  NCT03431350· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

  NCT03562169· Phase 3· University of Leeds· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

  NCT03006068· Phase 3· AbbVie· Source

• Active, not recruiting

  CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)

  NCT04116047· Phase 3· University of Birmingham· Source

• Active, not recruiting

  Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma

  NCT02315716· Phase 2· University College, London· Source

• Active, not recruiting

  Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

  NCT02446444· Phase 3· University of Sydney· Source

• Active, not recruiting

  Prostate Advances in Comparative Evidence

  NCT01584258· Phase 3· Royal Marsden NHS Foundation Trust· Source

• Active, not recruiting

  Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy

  NCT00268476· Phase 2/3· Medical Research Council· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease2 recruiting
• Childhood cancers1 recruiting
• Endometrial cancer1 recruiting
• High blood pressure1 recruiting
• Lung cancer1 recruiting
• Multiple myeloma1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Stroke1 recruiting
• Thyroid cancer1 recruiting
• Type 1 diabetes1 recruiting

Closed trials

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  OptimiZation Of Lipid Lowering Therapies Using a Decision Support System In Patients With Acute Coronary Syndrome.

  NCT05844566· Imperial College London· Source

• Terminated

  Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

  NCT04854096· Phase 2· NS Pharma, Inc.· Source

• Completed

  An Observational Study to Assess the Real-World Effectiveness of Upadacitinib in Adult Participants With Rheumatoid Arthritis

  NCT05170646· AbbVie· Source

• Completed

  Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR

  NCT04295577· Royal Marsden NHS Foundation Trust· Source

• Recruiting

  A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

  NCT04104776· Phase 1/2· Novartis Pharmaceuticals· Source

• Completed

  Paediatric Peri-operative Anxiety: Does the Little Journey App Help?

  NCT03797716· University College, London· Source

• Completed

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· Phase 3· Amgen· Source

• Completed

  A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

  NCT03782207· Hoffmann-La Roche· Source

• Completed

  A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug

  NCT03104374· Phase 3· AbbVie· Source

• Completed

  Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

  NCT03117933· Phase 2· University of Oxford· Source

• Completed

  Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer

  NCT03048942· Phase 2· University Hospitals Bristol and Weston NHS Foundation Trust· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Ankylosing spondylitis8 works · 0 trials